0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Contribution |

Concurrent Infection of the Central Nervous System by Borrelia burgdorferi and Bartonella henselae:  Evidence for a Novel Tick-borne Disease Complex FREE

Eugene Eskow, MD; Raja-Vemkitesh S. Rao, PhD; Eli Mordechai, PhD
[+] Author Affiliations

From Hunterdon Medical Center (Dr Eskow) and the Vector-Borne Disease Research Institute LLC (Drs Eskow and Mordechai), Flemington, NJ, and the Medical Diagnostic Laboratories LLC, Mt Laurel, NJ (Drs Rao and Mordechai).


Arch Neurol. 2001;58(9):1357-1363. doi:10.1001/archneur.58.9.1357.
Text Size: A A A
Published online

Objectives  To investigate Bartonella henselae as a potential human tick-borne pathogen and to evaluate its role as a coinfecting agent of the central nervous system in the presence of neuroborreliosis.

Design  Case report study.

Setting  A primary health care center in Flemington, NJ, and the Department of Research and Development at Medical Diagnostic Laboratories LLC in Mt Laurel, NJ.

Subjects  Two male patients (aged 14 and 36 years) and 2 female patients (aged 15 and 30 years, respectively) with a history of tick bites and Lyme disease.

Main Outcome Measures  Laboratory and diagnostic findings before and after antimicrobial therapy.

Results  Patients residing in a Lyme-endemic area of New Jersey with ongoing symptoms attributed to chronic Lyme disease were evaluated for possible coinfection with Bartonella species. Elevated levels of B henselae–specific antibodies were found in these patients using the immunofluorescent assay. Bartonella henselae–specific DNA was detected in their blood. None of these patients exhibited the clinical characteristics of cat-scratch disease. Findings of cerebrospinal fluid analysis revealed the presence of both B henselae– and Borrelia burgdorferi–specific DNA. Bartonella henselae–specific DNA was also detected in live deer ticks obtained from the households of 2 of these patients.

Conclusions  Our data implicate B henselae as a potential human tick-borne pathogen. Patients with a history of neuroborreliosis who have incomplete resolution of symptoms should be evaluated for B henselae infection.

Figures in this Article

LYME DISEASE is a tick-borne spirochetal disease caused by Borrelia burgdorferi and first recognized in this country in 1975 among children with acute arthritis in southeastern Connecticut. It is now the most commonly reported tick-borne illness in the United States. There are myriad potential neurologic manifestations, including aseptic meningitis, encephalitis, demyelinating encephalopathy, chorea, ataxia, seizures, cranial nerve palsies, myelitis, Guillain-Barré syndrome, mononeuritis multiplex, and benign intracranial hypertension.1 Mild chronic encephalopathy may be the most common neurologic symptom in patients with late-stage Lyme disease. The symptoms tend to be diffuse and nonspecific, and patients typically report memory loss, sleep disturbance, fatigue, and depression.2 The chronicity of these symptoms, despite parenteral antibiotic therapy, is well known to clinicians with experience in neuroborreliosis treatment.3 The cause of these persistent neurologic symptoms continues to be elusive.

Infections with Bartonella species have been reported in both immunocompromised and immunocompetent hosts. A wide spectrum of disease has been described in immunocompetent individuals, including bacillary angiomatosis, peliosis hepatitis, lymphadenitis, and aseptic meningitis with bacteremia and cat-scratch disease.4Bartonella species are vector-transmitted, blood-borne, intracellular, gram-negative bacteria that can induce prolonged infection in the host. Persistent infections in domestic and wild animals result in a substantial reservoir of Bartonella organisms in nature that can serve as a source for inadvertent human infection.5 The prevalence of bacteremia can range from 50% to 95% in select rodent, cat, deer, and cattle populations.5

It has been speculated that ongoing symptoms in chronic Lyme disease may be caused by a second tick-borne pathogen.6 A recent study from the Netherlands found a surprisingly high percentage of Ixodes ricinus ticks infected by Bartonella species.7Bartonella-specific DNA has also been amplified from I ricinus ticks in Poland.8 A novel Bartonella species has been found in the blood of wild mice (Peromyscus leucopus) exclusively in conjunction with B burgdorferi and Babesia microti.9 These findings have generated interest in the role of Bartonella species as a possible human tick-borne pathogen.

Our study was based on clinical and laboratory data obtained from patients with chronic Lyme disease residing in central New Jersey. These patients exhibited a variety of ongoing symptoms despite previous courses of antibiotic therapy. One of the coinvestigators, who was unaware of the clinical status of the study subjects, conducted polymerase chain reaction (PCR) analyses of cerebrospinal fluid (CSF) for both B burgdorferi and Bartonella species. Polymerase chain reaction amplifications were also performed on Ixodes scapularis ticks obtained from the households of 2 of these patients. The clinical course of these patients is described.

BLOOD SAMPLES AND ISOLATION OF PERIPHERAL BLOOD LYMPHOCYTES

Venous blood (10 mL) was obtained by venipuncture and collected in a yellow-top tube (ACD solution A; Becton Dickinson, Franklin Lakes, NJ). Peripheral blood lymphocytes were isolated by the Ficoll-Hypaque gradient centrifugation of the blood (Sigma Chemical, St Louis, Mo) at 1600 rpm for 30 minutes, in a Centra CL2 labtop centrifuge (Fisher Scientific, Pittsburgh, Pa). The lymphocyte ring was isolated and rinsed twice with phosphate-buffered saline, and cells were stained with trypan blue to determine cellular viability.

LYME DISEASE SEROLOGIC EVALUATION

Serum samples were obtained from all 4 individuals and assayed by Western blot analysis for B burgdorferi IgG and IgM using the commercially available Marblot strip test system (MarDx Diagnostics, Carlsbad, Calif). The interpretation of B burgdorferi Western blot results satisfied the surveillance case definition of B burgdorferi infection of the Centers for Disease Control and Prevention.

DNA EXTRACTION

The lymphocytes were dissolved in 470 µL of tris-EDTA buffer (10 mM tris-hydrochloride [pH, 8.0] and 1 mM EDTA), 25 µL of 10% sodium dodecyl sulfate, and 12 µL of freshly prepared deoxyonuclease-free proteinase K (10 mg/mL). The mixture was incubated at 55°C for 2 hours; DNA was extracted by phenolchloroform extraction and ethanol precipitation. The purified DNA was dissolved in pyrogen-free, double-distilled water, and quantified using a Genesys-5 spectrophotometer (Spectronic Instruments, Rochester, NY). The purified, quantitated DNA was used as a template for Bartonella henselae and B burgdorferi PCR analysis. Nucleic acid was extracted for Ehrlichia PCR testing by the DNAzol method (Invitrogen; Molecular Research Center Inc, Grand Island, NY), as described by the manufacturer. The DNA extraction process for B microti from human blood specimens was described by Persing et al.10 Briefly, whole blood (1 mL) was treated with TE, hypotonic lysis solution (10 mM tris [pH, 7.4] and 1 mM EDTA) and then centrifuged (at room temperature, 16 000g, for 5 minutes). The pellet was washed 3 times with TE, taking care to remove the erythrocyte ghost layer after each wash. To the pellet was added 200 µL of buffer K (50 mM tris [pH, 8.3], 1.5 mM magnesium chloride, 0.45% nonidet P-40, 0.45% Tween 20, and 10 µg of proteinase K per milliliter). The pellet was dispersed by vortexing and incubated at 55°C for 1 hour, at 95°C for 10 minutes to inactivate the protease and denature the genomic target DNA, and then cooled immediately on ice. The purified, quantitated DNA was used as a template for B microti PCR analysis.

PRIMERS

The PCR primers for the identification of B henselae,11B burgdorferi,12B microti,10 and Ehrlichia13 have been described. The sensitivity and specificity of the B burgdorferi primers are well described.14 No statistically significant differences between chromosomal gene primer pairs and plasmid primer pairs were seen in CSF and skin specimens.14 The primers were synthesized by Research Genetics (Huntsville, Ala) and purified by high-performance liquid chromatography. Their sequences are given in Table 1.

Table Graphic Jump LocationTable 1. Sequences and Positions of Oligonucleotide Primers Used for Bartonella henselae Polymerase Chain Reaction Amplification
POLYMERASE CHAIN REACTION

The PCR mixtures (50 µL) contained extracted DNA (5 µL, 0.2 µg/µL), P24E and P12B primers (50 nM), 10 mM tris-hydrochloride (pH, 8.3), 50 mM potassium chloride, 3 mM magnesium chloride, 0.001% (wt/vol) gelatin, the nucleotides dATP, dCTP, dGTP, and dTTP (each at a concentration of 200 mmol/L), and 2.5 U of Taq DNA polymerase (Perkin-Elmer, Foster City, Calif). The PCR was carried out in 0.2-mL tubes. The thermocycler was a Perkin-Elmer GeneAMP PCR system 2400. The PCR program ran for 3 minutes at 94°C, followed by 40 one-minute cycles at 94°C, 1 minute at 56°C, and 1.5 minutes at 72°C. The program finished with an additional 10-minute extension step at 72°C. A 30-µL sample of the final reaction product was run on 1% agarose gel containing 0.5 µg of ethidium bromide per milliliter, and the gel was photographed under UV light. For optimization of the PCR conditions for clinical specimens, normal blood was artificially spiked with in vitro–cultivated B henselae. A controlled number of B henselae (American Type Culture Collection 49882, ATCC, Rockville, Md), ranging from 10 to 105 pathogens was added to 5 mL of whole blood. These spiked samples were treated as described above. The PCR analysis of B burgdorferi, B microti, and Ehrlichia was carried out as described.10,12,13

HISTONE PCR

Aliquots (5 µL) of the newly extracted DNA were mixed in a 50-µL PCR reaction mixture containing 10× PCR buffer (Perkin Elmer), 3 mM magnesium chloride, 200 mM dNTP, 2.5 µL of Taq DNA polymerase (5 U/µL), and 1 µL (8 pmol) of 5′- and 3′histone amplifier primer set. The histone primers are complementary to the DNA of a constitutively expressed human histone gene H3.3 as described.15 The amplification process was subjected to 30 cycles of PCR (each cycle at 94°C for 45 seconds, 60°C for 45 seconds, and 72°C for 90 seconds) in a 2400 Perkin-Elmer DNA thermocycler. The histone primers served as internal controls for the sample's DNA integrity, presence of inhibitors, and intersample equivalency of total amount of DNA analyzed.

PRECAUTIONS AGAINST CONTAMINATION

The extraction of DNA and PCR were performed under sterile conditions and in separate rooms. In addition, all positive samples were confirmed by reextraction from the original sample, followed by amplification in triplicate. Bartonella henselae DNA–positive status was defined as samples that were positive initially, and in at least 1 of the replicates after reextraction. Pyrogen-free water was used in the isolation of DNA from the blood specimen. The Eppendorff microcentrifuge tubes and the PCR tubes were sterilized in an autoclave and UV irradiated. New Finn pipettes were used solely with the filter tips for PCR. Disposable plastic trays were used to prepare PCRs in a UV-irradiated PCR biohood. Blood and CSF samples (n = 10: 5 of CSF and 5 of blood) from individuals with no evidence of tick-borne disease were used in the PCR assays as negative controls. In addition, the patients in this study were the first in our laboratory to test positive for B henselae.

CASE 1

Our first patient was a previously healthy 14-year-old male adolescent who developed gradually worsening frontal headaches, fatigue, and knee arthralgia. These symptoms were accompanied by low-grade fever, insomnia, and the inability to concentrate in school. He revealed that 3 months prior to the onset of illness, a small tick was removed from his scalp. However, he did not seek medical attention at that time.

Results of initial testing for Lyme disease and babesiosis were negative. There was no improvement in his symptoms following a trial of therapy with doxycycline hyclate (200 mg/d for 6 weeks). The patient was unable to attend school owing to severe fatigue, headaches, and cognitive dysfunction. He was previously an excellent student with rare absences from school. Computed tomographic scans of the brain revealed no distinct abnormality.

Results of further testing revealed B henselae in the blood (IgG titer, 1:64 using the immunofluorescence assay [IFA]). Bartonella henselae–specific DNA was successfully amplified from his blood and CSF (atraumatic spinal tap). Interestingly, results of PCR analysis of this same CSF specimen were positive for B burgdorferi–specific DNA. It should be noted that the patient denied exposure to cats in the months preceding his illness. He was treated with a 6-week course of cefotaxime sodium (6 g/d) and experienced a prompt resolution of his symptoms.

During his therapy, a live deer tick (I scapularis) was found in his household. Findings of PCR analysis of this tick were positive for both B henselae– and B burgdorferi–specific DNA.

CASE 2

A 36-year-old man presented with a history of late-stage Lyme disease. He remained symptomatic despite receiving an 8-week course of intravenous ceftriaxone sodium (2 g/d). Specifically, he continued to report frontal headaches, fatigue, recent memory loss, depression, and arthralgia. He also reported episodes of confusion and a markedly shortened attention span. He was disabled from his job as a truck driver for a period of several months. Magnetic resonance images of his brain revealed no distinct abnormality. He exhibited positive B henselae serologic test results (IgG ratio, 1:128 using IFA). Bartonella henselae–specific DNA was successfully amplified from his blood. Lumbar puncture was performed, and PCR findings revealed the presence of both B henselae– and B burgdorferi–specific DNA in the same CSF sample. Therapy was initiated with intravenous cefotaxime sodium (8 g/d for 28 days). He became more lucid, and his ability to concentrate improved. He also reported improvement in his recent memory and resolution of headache.

However, his arthralgia persisted throughout his therapy. A second lumbar puncture was done after 28 days of cefotaxime treatment. The 16S ribosomal RNA of B henselae was successfully amplified from DNA isolated from peripheral blood lymphocytes and CSF (Figure 1, lanes 1 and 2, respectively). Twenty-eight days after antimicrobial therapy, B henselae DNA was not detected in the blood and CSF of this patient (Figure 1, lanes 3 and 4 to 5, respectively). To increase the sensitivity of our PCR, the amount of input DNA isolated from the CSF was doubled. Bartonella henselae DNA was not detected after therapy (Figure 1, lane 5). In addition, B burgdorferi DNA was no longer detected (data not shown).

Place holder to copy figure label and caption
Figure 1.

Detection of a Bartonella henselae–specific DNA target in DNA isolated from the blood and cerebrospinal fluid (CSF) of naturally infected individuals (case reports) before and after antimicrobial therapy. A specific primer pair was derived from the B henselae 16S ribosomal RNA gene fragment. The arrow indicates a B henselae–specific polymerase chain reaction (PCR) product of 279 base pairs (bp). Aliquots of DNA isolated from blood (lanes 1 and 3) and CSF (lanes 2 and 4 to 5) were subjected to B henselae amplification before and after antimicrobial therapy (lanes 1 and 2 and 3 to 5, respectively). Lane M contains a 100-bp ladder DNA marker. The positive control (lane 6) contains an American Type Culture Collection B henselae–positive control. The negative control (lane 7) contains a control for the PCR.

Graphic Jump Location
CASE 3

The third patient was a 15-year-old female adolescent with a history of Lyme disease treated with an 8-week course of doxycycline hyclate (200 mg/d). Following this therapy, the patient developed a gradual recurrence of symptoms over a 3-month period. She described arthralgia primarily affecting the hips, knees, and ankle joints. These symptoms were accompanied by fatigue, night sweats, headache, photophobia, menstrual irregularity, depressed mood, dizziness, insomnia, and the inability to concentrate in school. She was previously an excellent student, but she was unable to attend school for a 2-month period owing to this symptom complex.

There was no history of cat exposure and no known history of tick bite. Bartonella henselae serologic testing was done, and the results revealed the presence of B henselae–specific antibodies (IgG titer, 1:64 using IFA). Neuroborreliosis was suspected, and a lumbar puncture was performed. Results of CSF analysis revealed the presence of both B burgdorferi– (Figure 2, lane 1, before antimicrobial therapy) and B henselae–specific DNA (PCR method). Treatment was initiated with a 28-day course of intravenous ceftriaxone sodium (2 g/d). The patient experienced symptomatic improvement by the end of the ceftriaxone regimen, and a second lumbar puncture was done. Borrelia burgdorferi–specific DNA was no longer detectable (Figure 2, lane 4, after antimicrobial therapy); however, B henselae–specific DNA persisted. It should be mentioned that this lumbar puncture was atraumatic (0 red blood cells per high-power field).

Place holder to copy figure label and caption
Figure 2.

Detection of a Borrelia burgdorferi–specific DNA target from DNA isolated from the cerebrospinal fluid (CSF) of patient 3 before (lane 1) and after (lane 4) antimicrobial therapy. The arrow indicates a B burgdorferi–specific polymerase chain reaction (PCR) product of 231 base pairs (bp). Aliquots of DNA isolated from CSF before and after antimicrobial therapy (lane 1 and lane 4, respectively) were subjected to B burgdorferi amplification. Both M lanes contain a 100-bp ladder DNA marker. The positive controls (lanes 2 and 5) contain an American Type Culture Collection B burgdorferi–positive control. The negative controls (lanes 3 and 6) contain all the PCR components without DNA.

Graphic Jump Location

At this point, treatment was changed to intravenous doxycycline hyclate (100 mg every 12 hours). Most of her previously mentioned symptoms returned within 3 days of starting doxycycline therapy, including confusion and the inability to concentrate. Antibiotic therapy was changed to intravenous azithromycin (500 mg/d for 14 days). Her symptoms resolved promptly under azithromycin treatment. Specifically, her ability to read and perform mathematical tasks improved greatly. She reported improvement in memory, more restful sleep, and no further headache.

CASE 4

Our fourth study subject was a 30-year-old woman who became ill within a week after the removal of 2 ticks from her skin. She complained of fever, frontal headache, dizziness, fatigue, and upper extremity arthralgia. She noticed several small ticks on her pet cat, and these were subsequently identified as I scapularis. These ticks were positive for B henselae–specific DNA and negative for B burgdorferi–specific DNA. Her headaches and dizziness intensified, and computed tomographic images of the brain were taken, which revealed no distinct brain abnormality. Nonetheless, her neurologic symptoms persisted. Bartonella henselae was found on serologic testing (IgG titer, 1:256 using IFA). Bartonella henselae–specific DNA was amplified from her blood.

This patient exhibited no laboratory evidence of babesiosis, ehrlichiosis, or Lyme disease by PCR or Western blot analysis. Lumbar puncture was performed, and findings of CSF analysis were negative for B burgdorferi– and B henselae–specific DNA. She was treated with a 28-day course of oral doxycycline hyclate (300 mg/d), and her symptoms resolved during that period.

In summary, the common symptoms before therapy for all 4 patients were cognitive dysfunction, headache, and fatigue. All of our study subjects had a clinical presentation consistent with mild encephalopathy (Table 2). After antimicrobial therapy, our study subjects exhibited improved cognitive function, resolution of headaches, and a marked improvement in energy levels (Table 3).

Table Graphic Jump LocationTable 2. Summary of Pretreatment Laboratory Data and Symptoms*
Table Graphic Jump LocationTable 3. Summary of Posttreatment Laboratory Data and Symptoms*

Both B henselae and B burgdorferi have a well-established ability to infect the central nervous system, with a variety of resultant neurologic consequences. Cases of encephalopathy due to B henselae infection have been well described.1618 Patients typically complain of persistent generalized headache and restlessness and may present with combative behavior.19 Nearly half of these patients with encephalopathy can develop seizures that may range from focal to generalized, and from brief and self-limited to status epilepticus. Bartonella henselae–induced encephalopathy may be a relatively frequent cause of status epilepticus in school-aged children.20 The ability of this pathogen to cause persistent dementia following encephalitis has been demonstrated.21 Neuroophthalmic effects, including loss of vision, have been well documented.2225

Cat-scratch disease is the most commonly recognized manifestation of human infection with B henselae. Interestingly, none of our study subjects displayed the clinical characteristics of cat-scratch disease. There have been no previously reported cases of tick-borne B henselae infection in humans. Vector competency has not been clearly established for tick species, and knowledge related to vector transmission of Bartonellaorganisms is very incomplete.5 Vector-mediated transmission of B henselae to cats via fleas has been demonstrated.26 Three of our study subjects had no prior exposure to cats. Our fourth patient removed several small ticks from her cat, and these tested positive for B henselae using PCR. This case was included in our study to illustrate that B henselae infection could be acquired as a tick-borne disease independent of B burgdorferi infection. One of our patients found a live deer tick in his household that tested positive on PCR analysis for both B henselae and B burgdorferi. These findings implicate the deer tick as a potential carrier of B henselae.

Three of our patients had a history of chronic Lyme disease with persistent symptoms despite previous attempts at antibiotic therapy. The concurrent finding of B henselae– and B burgdorferi–specific DNA in their CSF probably explains their prior lack of response to antibiotic therapy directed exclusively at Lyme disease. There were 8 CSF samples obtained from other patients during the same period that were negative for both B burgdorferi and B henselae using PCR analysis. Our third patient had persistently detectable B henselae–specific DNA in spinal fluid after a 28-day course of ceftriaxone therapy. Our second patient demonstrated the absence of both B henselae– and B burgdorferi–specific DNA after a 28-day course of cefotaxime treatment. Interestingly, B henselae has been shown to have in vitro susceptibility to cefotaxime (minimal inhibitory concentration [MIC90] of 0.25 µg/mL).27 One of our patients exhibited prompt resolution of symptoms with a trial of azithromycin. A prospective, randomized, double-blind, placebo-controlled study has demonstrated azithromycin's efficacy against B henselae.28 The report by Bass et al28 has been the only study of its kind describing the efficacy of azithromycin against B henselae.

All of our patients were tested for other tick-borne diseases (Babesia and Ehrlichia). The results were negative on PCR analysis (data not shown). All of our patients exhibited varying levels of B henselae–specific antibodies on IFA. However, in a significant number of cases, the diagnosis cannot be made on the basis of IFA antibody testing alone.29 Serologic testing was performed, including for IgM, and the IgM results were negative in these 4 cases. The limitations of serologic testing for B henselae have been described.30 The sensitivity of culture for this organism is low when compared with PCR-based detection methods.31 Polymerase chain reaction detection of B henselae is especially useful in cases with a broad differential diagnosis32,33 and PCR played a pivotal diagnostic role in our study.

Despite antibiotic treatment, some patients with Lyme disease persistently exhibit symptoms associated with chronic Lyme disease syndrome or post-Lyme syndrome. These symptoms include neurocognitive impairment, persistent arthralgia, fatigue, and subjective memory loss.34 The persistent symptomatology might be attributed to several factors. First, coinfections: in addition to transmitting B burgdorferi, a tick may harbor other pathogens, including Babesia, Ehrlichia, and Bartonella species.9 These multiple pathogens may survive Lyme antimicrobial therapy and be responsible for the persistent symptoms in individuals with post-Lyme syndrome. The importance of considering these coinfecting agents in the differential diagnosis cannot be overstated. Second, genetic predisposition might play a role in chronicity, pathogenesis, antimicrobial resistance, and prognosis for patients with Lyme disease.

There have been no previously reported cases of concurrent Lyme disease and B henselae infection. The zoonotic potential for human infection with Bartonella species has recently been well described.5 High levels of bacteremia are currently being documented in numerous domestic and wild animal species.5 Our data implicate B henselae as yet another tick-borne pathogen. Further vector competency studies are needed. The fact that our cases of concomitant central nervous system infection with B henselae and B burgdorferi were diagnosed in a 1-month period suggests that these coinfections may occur relatively frequently.

Acquisition of simultaneous coinfection of B burgdorferi and Ehrlichia or Babesia by I scapularis ticks is well documented.3538 It was shown that the presence of either B burgdorferi or human granulocytic ehrlichiosis (HGE) in I scapularis ticks did not affect acquisition of the other agents from an infected host. In addition, transmission of the agents of Lyme disease and HGE by individual ticks was equally efficient and independent. Immunoserologic evidence of coinfection with B burgdorferi, Babesia, and HGE among individuals in tick-endemic areas is well documented. In one study it was reported that of 96 patients with Lyme borreloisis, 9 (9.4%) demonstrated immunoserologic evidence of coinfection.38

The results presented herein provide evidence for coinfection, perhaps explaining the variable manifestations and clinical responses noted in some patients with tick-borne diseases. In certain clinical settings, laboratory testing for coinfection is of great value to ensure that appropriate antimicrobial treatment is given. Clinicians continue to be challenged to explain the pathophysiology behind chronic Lyme disease. Persistent symptoms following even aggressive therapy for Lyme disease continue to frustrate both patients and their physicians. We put forth concurrent B henselae infection as one reason for ongoing symptoms in chronic Lyme disease. We consider this an introductory study and look forward to a more comprehensive evaluation of the role B henselae plays as a coinfecting agent in chronic Lyme disease. However, we are convinced that concomitant B henselae infection should be considered in neuroborreliosis cases refractory to standard therapy.

Accepted for publication May 24, 2001.

Corresponding author and reprints: Eli Mordechai, PhD, Medical Diagnostic Laboratories LLC, 133 Gaither Dr, Suite C, Mt Laurel, NJ 08054 (e-mail: emordechai@aol.com).

Bell  WE Parasitic infections of the brain.  In: Rudolph  A, Hoffman  J, Rudolph  C, eds. Rudolph's Pediatrics.19th ed. Norwalk, Conn: Appleton & Lange; 1991:29.20.7.
Kaplan  RFJones-Woodward  L Lyme encephalopathy: a neuropsychological perspective. Semin Neurol.1997;17:31-37.
Treb  JFernandez  AHaass  AGraner  MTHolzer  GWoessner  R Clinical and serologic follow-up in patients with neuroborreliosis. Neurology.1998;51:1489-1491.
Wong  MTDolan  MJLattuada  CP  et al Neuroretinitis, aseptic meningitis, and lymphadenitis associated with Bartonella (Rochalimaea) henselae infection in immunocompetent patients and patients infected with human immunodeficiency virus type 1. Clin Infect Dis.1995;21:352-360.
Breitschwerd  EBKordick  DL Bartonella infection in animals: carriership, reservoir potential, pathogenicity, and zoonotic potential for human infection. Clin Microbiol Rev.2000;13:428-438.
National Institute of Allergy and Infectious Diseases Research on Chronic Lyme Disease.  Bethesda, Md: National Institute of Allergy and Infectious Diseases; May1997. NIAID Fact Sheet 1-3.
Schouls  LMVan De Pol  IRijpkema  SGSchot  CS Detection and identification of Ehrlichia, Borrelia burgdorferi sensu lato, and Bartonella species in Dutch Ixodes ricinus ticks. J Clin Microbiol.1999;37:2215-2222.
Kruszewska  DTylewska-Wierbanowska  S Unknown species of Rickettsiae isolated from the Ixodes ricinus tick in Walcz. Rocz Aked Med Bialymst.1996;41:129-135.
Hofmeister  EKKolbert  CPAbdulkarim  AS  et al Co-segregation of a novel Bartonella species with Borrelia burgdorferi and Babesia microti in Peromyscus leucopusJ Infect Dis.1998;177:409-416.
Persing  DHMathiesen  DMarshall  WF  et al Detection of Babesia microti by polymerase chain reaction. J Clin Microbiol.1992;30:2097-2103.
Relman  DALoutit  JSSchmidt  TMFalkow  STompkins  LS The agent of bacillary angiomatosis. N Engl J Med.1990;323:1573-1580.
Cogswell  FBBanter  CEHughes  TG  et al Host DNA can interfere with detection of Borrelia burgdorferi in skin biopsy specimens by PCR. J Clin Microbiol.1996;34:980-982.
Chu  FK Rapid and sensitive PCR-based detection and differentiation of aetiologic agents of human granulocytotropic and monototropic ehrlichiosis. Mol Cell Probes.1998;12:93-99.
Schmidt  BL PCR in laboratory diagnosis of human Borrelia burgdorferiClin Microbiol Rev.1997;10:185-201.
Pieper  ROFutscher  BWDong  QEllis  TMErickson  LC Comparison of O-6 methylguanine DNA methyltransferase (MGMT) mRNA levels in Mer-human tumor cell lines containing the MGMT gene by the polymerase chain reaction technique. Cancer Commun.1990;2:13-20.
Wheeler  SWWolf  SMSteinberg  EA Cat-scratch encephalopathy [comments]. Neurology.1997;49:876-878.
Silver  BEBean  CS Cat-scratch encephalopathy. Del Med J.1991;63:365-368.
Yagupsky  PSofer  S Cat-scratch encephalopathy presenting as status epilepticus and lymphadenitis. Pediatr Emerg Care.1990;6:43-45.
Harvey  RAMisselbeck  WJUphold  RE Cat-scratch disease: an unusual cause of combative behavior. Am J Emerg Med.1991;9:52-53.
Armengol  CEHendley  JD Cat-scratch disease encephalopathy: a cause of status epilepticus in school-aged children. J Pediatr.1999;134:635-638.
Revol  AVighetto  AJonvet  AAimard  GTrillet  M Encephalitis in cat-scratch disease with persistent dementia. J Neurol Neurosurg Psychiatry.1992;55:133-135.
Chrousos  GADrak  AVYoung  MKattah  JSirdofsky  M Neuroretinitis in cat-scratch disease. J Clin Neuroophthalmol.1990;10:92-94.
Gray  AVReed  JBWendel  RTMarse  LS Bartonella henselae infection associated with peripapillary angioma, branch retinol artery occlusion, and severe vision loss. Am J Ophthalmol.1999;127:223-224.
Golnik  KCMarotto  MEFanons  MM  et al Ophthalmic manifestations of Rochalimaea species [comments]. Am J Ophthalmol.1994;118:145-151.
Reed  JBScales  DKWong  MTCattuada Jr  CPDolan  MJSchwab  IR Bartonella henselae neuroretinitis in cat-scratch disease: diagnosis, management, and sequelae [comments]. Ophthalmology.1998;105:459-466.
Chomel  BBKasten  RWFloyd-Hawkins  K  et al Experimental transmission of Bartonella henselae by the cat flea. J Clin Microbiol.1996;34:1952-1956.
Maurin  MGasquet  SDucco  CRaoult  D MICs of 28 antibiotic compounds for 14 Bartonella (formerly Rochalimaea) isolates. Antimicrob Agents Chemother.1995;39:2387-2391.
Bass  JWFreitas  BCFreitas  AD  et al Prospective randomized double-blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J.1998;17:447-452.
Flexman  JPChen  SCDickeson  DJPearman  JWGilbert  GL Detection of antibodies to Bartonella henselae in clinically diagnosed cat-scratch disease. Med J Aust.1997;166:532-535.
Bergmans  AMPeters  MFSchellekens  JF  et al Pitfalls and fallacies of cat-scratch disease serology: evaluation of Bartonella henselae–based indirect fluorescence assay and enzyme-linked immunoassay. J Clin Microbiol.1997;35:1931-1937.
LaScola  BRaoult  D Culture of Bartonella quintana and Bartonella henselae from human samples: a 5-year experience (1993 to 1998). J Clin Microbiol.1999;37:1899-1905.
Gottlieb  TAtkins  BLRobson  JM Cat-scratch disease diagnosed by polymerase chain reaction in a patient with suspected tuberculous lymphadenitis. Med J Aust.1999;170:168-170.
George  TIManley  GKoehler  JEHung  VSMcDermott  MBollen  A Detection of Bartonella henselae by polymerase chain reaction in brain tissue of an immunocompromised patient with multiple enhancing lesions: case report and review of the literature. J Neurosurg.1998;89:640-644.
Bujak  DIWeinstein  ADornbush  RL Clinical and neurocognitive features of the post Lyme syndrome. J Rheumatol.1996;23:1392-1397.
Levin  MLFish  D Acquisition of coinfection and simultaneous transmission of Borrelia burgdorferi and Ehrlichia phagocytophobia by Ixodes scapularis ticks. Infect Immun.2000;68:2183-2186.
Belongia  EAReed  KDMitchell  PD  et al Clinical and epidemiological features of early Lyme disease and human granulocytic ehrlichiosis in Wisconsin. Clin Infect Dis.1999;29:1472-1477.
Magnarelli  LADumler  JSAnderson  JF  et al Coexistence of antibodies to tick-borne pathogens of babesiosis, ehrlichiosis, and Lyme borreliosis in human sera. J Clin Microbiol.1995;33:3054-3057.
Mitchell  PDReed  KDHofkes  JM Immunoserologic evidence of coinfection with Borrelia burgdorferi, Babesia microti, and human granulocytic Ehrlichia species in residents of Wisconsin and Minnesota. J Clin Microbiol.1996;34:724-727.

Figures

Place holder to copy figure label and caption
Figure 1.

Detection of a Bartonella henselae–specific DNA target in DNA isolated from the blood and cerebrospinal fluid (CSF) of naturally infected individuals (case reports) before and after antimicrobial therapy. A specific primer pair was derived from the B henselae 16S ribosomal RNA gene fragment. The arrow indicates a B henselae–specific polymerase chain reaction (PCR) product of 279 base pairs (bp). Aliquots of DNA isolated from blood (lanes 1 and 3) and CSF (lanes 2 and 4 to 5) were subjected to B henselae amplification before and after antimicrobial therapy (lanes 1 and 2 and 3 to 5, respectively). Lane M contains a 100-bp ladder DNA marker. The positive control (lane 6) contains an American Type Culture Collection B henselae–positive control. The negative control (lane 7) contains a control for the PCR.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Detection of a Borrelia burgdorferi–specific DNA target from DNA isolated from the cerebrospinal fluid (CSF) of patient 3 before (lane 1) and after (lane 4) antimicrobial therapy. The arrow indicates a B burgdorferi–specific polymerase chain reaction (PCR) product of 231 base pairs (bp). Aliquots of DNA isolated from CSF before and after antimicrobial therapy (lane 1 and lane 4, respectively) were subjected to B burgdorferi amplification. Both M lanes contain a 100-bp ladder DNA marker. The positive controls (lanes 2 and 5) contain an American Type Culture Collection B burgdorferi–positive control. The negative controls (lanes 3 and 6) contain all the PCR components without DNA.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable 1. Sequences and Positions of Oligonucleotide Primers Used for Bartonella henselae Polymerase Chain Reaction Amplification
Table Graphic Jump LocationTable 2. Summary of Pretreatment Laboratory Data and Symptoms*
Table Graphic Jump LocationTable 3. Summary of Posttreatment Laboratory Data and Symptoms*

References

Bell  WE Parasitic infections of the brain.  In: Rudolph  A, Hoffman  J, Rudolph  C, eds. Rudolph's Pediatrics.19th ed. Norwalk, Conn: Appleton & Lange; 1991:29.20.7.
Kaplan  RFJones-Woodward  L Lyme encephalopathy: a neuropsychological perspective. Semin Neurol.1997;17:31-37.
Treb  JFernandez  AHaass  AGraner  MTHolzer  GWoessner  R Clinical and serologic follow-up in patients with neuroborreliosis. Neurology.1998;51:1489-1491.
Wong  MTDolan  MJLattuada  CP  et al Neuroretinitis, aseptic meningitis, and lymphadenitis associated with Bartonella (Rochalimaea) henselae infection in immunocompetent patients and patients infected with human immunodeficiency virus type 1. Clin Infect Dis.1995;21:352-360.
Breitschwerd  EBKordick  DL Bartonella infection in animals: carriership, reservoir potential, pathogenicity, and zoonotic potential for human infection. Clin Microbiol Rev.2000;13:428-438.
National Institute of Allergy and Infectious Diseases Research on Chronic Lyme Disease.  Bethesda, Md: National Institute of Allergy and Infectious Diseases; May1997. NIAID Fact Sheet 1-3.
Schouls  LMVan De Pol  IRijpkema  SGSchot  CS Detection and identification of Ehrlichia, Borrelia burgdorferi sensu lato, and Bartonella species in Dutch Ixodes ricinus ticks. J Clin Microbiol.1999;37:2215-2222.
Kruszewska  DTylewska-Wierbanowska  S Unknown species of Rickettsiae isolated from the Ixodes ricinus tick in Walcz. Rocz Aked Med Bialymst.1996;41:129-135.
Hofmeister  EKKolbert  CPAbdulkarim  AS  et al Co-segregation of a novel Bartonella species with Borrelia burgdorferi and Babesia microti in Peromyscus leucopusJ Infect Dis.1998;177:409-416.
Persing  DHMathiesen  DMarshall  WF  et al Detection of Babesia microti by polymerase chain reaction. J Clin Microbiol.1992;30:2097-2103.
Relman  DALoutit  JSSchmidt  TMFalkow  STompkins  LS The agent of bacillary angiomatosis. N Engl J Med.1990;323:1573-1580.
Cogswell  FBBanter  CEHughes  TG  et al Host DNA can interfere with detection of Borrelia burgdorferi in skin biopsy specimens by PCR. J Clin Microbiol.1996;34:980-982.
Chu  FK Rapid and sensitive PCR-based detection and differentiation of aetiologic agents of human granulocytotropic and monototropic ehrlichiosis. Mol Cell Probes.1998;12:93-99.
Schmidt  BL PCR in laboratory diagnosis of human Borrelia burgdorferiClin Microbiol Rev.1997;10:185-201.
Pieper  ROFutscher  BWDong  QEllis  TMErickson  LC Comparison of O-6 methylguanine DNA methyltransferase (MGMT) mRNA levels in Mer-human tumor cell lines containing the MGMT gene by the polymerase chain reaction technique. Cancer Commun.1990;2:13-20.
Wheeler  SWWolf  SMSteinberg  EA Cat-scratch encephalopathy [comments]. Neurology.1997;49:876-878.
Silver  BEBean  CS Cat-scratch encephalopathy. Del Med J.1991;63:365-368.
Yagupsky  PSofer  S Cat-scratch encephalopathy presenting as status epilepticus and lymphadenitis. Pediatr Emerg Care.1990;6:43-45.
Harvey  RAMisselbeck  WJUphold  RE Cat-scratch disease: an unusual cause of combative behavior. Am J Emerg Med.1991;9:52-53.
Armengol  CEHendley  JD Cat-scratch disease encephalopathy: a cause of status epilepticus in school-aged children. J Pediatr.1999;134:635-638.
Revol  AVighetto  AJonvet  AAimard  GTrillet  M Encephalitis in cat-scratch disease with persistent dementia. J Neurol Neurosurg Psychiatry.1992;55:133-135.
Chrousos  GADrak  AVYoung  MKattah  JSirdofsky  M Neuroretinitis in cat-scratch disease. J Clin Neuroophthalmol.1990;10:92-94.
Gray  AVReed  JBWendel  RTMarse  LS Bartonella henselae infection associated with peripapillary angioma, branch retinol artery occlusion, and severe vision loss. Am J Ophthalmol.1999;127:223-224.
Golnik  KCMarotto  MEFanons  MM  et al Ophthalmic manifestations of Rochalimaea species [comments]. Am J Ophthalmol.1994;118:145-151.
Reed  JBScales  DKWong  MTCattuada Jr  CPDolan  MJSchwab  IR Bartonella henselae neuroretinitis in cat-scratch disease: diagnosis, management, and sequelae [comments]. Ophthalmology.1998;105:459-466.
Chomel  BBKasten  RWFloyd-Hawkins  K  et al Experimental transmission of Bartonella henselae by the cat flea. J Clin Microbiol.1996;34:1952-1956.
Maurin  MGasquet  SDucco  CRaoult  D MICs of 28 antibiotic compounds for 14 Bartonella (formerly Rochalimaea) isolates. Antimicrob Agents Chemother.1995;39:2387-2391.
Bass  JWFreitas  BCFreitas  AD  et al Prospective randomized double-blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J.1998;17:447-452.
Flexman  JPChen  SCDickeson  DJPearman  JWGilbert  GL Detection of antibodies to Bartonella henselae in clinically diagnosed cat-scratch disease. Med J Aust.1997;166:532-535.
Bergmans  AMPeters  MFSchellekens  JF  et al Pitfalls and fallacies of cat-scratch disease serology: evaluation of Bartonella henselae–based indirect fluorescence assay and enzyme-linked immunoassay. J Clin Microbiol.1997;35:1931-1937.
LaScola  BRaoult  D Culture of Bartonella quintana and Bartonella henselae from human samples: a 5-year experience (1993 to 1998). J Clin Microbiol.1999;37:1899-1905.
Gottlieb  TAtkins  BLRobson  JM Cat-scratch disease diagnosed by polymerase chain reaction in a patient with suspected tuberculous lymphadenitis. Med J Aust.1999;170:168-170.
George  TIManley  GKoehler  JEHung  VSMcDermott  MBollen  A Detection of Bartonella henselae by polymerase chain reaction in brain tissue of an immunocompromised patient with multiple enhancing lesions: case report and review of the literature. J Neurosurg.1998;89:640-644.
Bujak  DIWeinstein  ADornbush  RL Clinical and neurocognitive features of the post Lyme syndrome. J Rheumatol.1996;23:1392-1397.
Levin  MLFish  D Acquisition of coinfection and simultaneous transmission of Borrelia burgdorferi and Ehrlichia phagocytophobia by Ixodes scapularis ticks. Infect Immun.2000;68:2183-2186.
Belongia  EAReed  KDMitchell  PD  et al Clinical and epidemiological features of early Lyme disease and human granulocytic ehrlichiosis in Wisconsin. Clin Infect Dis.1999;29:1472-1477.
Magnarelli  LADumler  JSAnderson  JF  et al Coexistence of antibodies to tick-borne pathogens of babesiosis, ehrlichiosis, and Lyme borreliosis in human sera. J Clin Microbiol.1995;33:3054-3057.
Mitchell  PDReed  KDHofkes  JM Immunoserologic evidence of coinfection with Borrelia burgdorferi, Babesia microti, and human granulocytic Ehrlichia species in residents of Wisconsin and Minnesota. J Clin Microbiol.1996;34:724-727.

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 66

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Survey of tickborne infections in Denmark. Emerg Infect Dis 2005;11(7):1055-61.